HeartBeam Wins FDA Nod for Cable-Free 12-Lead ECG for Home Arrhythmia Assessment

HeartBeam has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 12-lead electrocardiogram (ECG) synthesis software to assess arrhythmias. The regulatory nod follows the company’s successful appeal of a prior Not Substantially Equivalent (NSE) determination.

The company’s cable-free technology, unlike any single-lead or six-lead consumer device, captures the heart’s electrical signals in three non-coplanar directions and synthesizes them into a 12-lead ECG representation. This lets patients gather an ECG reading for an arrhythmia from their home or wherever they happen to be.

The synthesized 12-lead ECG is then quickly reviewed by an on-demand, board-certified cardiologist.

“One of the biggest challenges in cardiology is that cardiac symptoms most often don’t happen in the doctor’s office—they happen at home, at night, at work,” said Robert A. Harrington, MD, a cardiologist and HeartBeam scientific advisory board member. “The ability for patients to collect clinically meaningful ECG data at that exact moment, not hours later, can allow physicians to gain a much clearer understanding of a patient’s condition and take more timely action. HeartBeam is designed to be easy to carry and easy for patients to use, representing an important step forward in cardiac care.”

With this clearance, HeartBeam plans to advance several key initiatives. The company expects to begin market introduction in early 2026, focusing on select concierge and preventive cardiology groups that have shown interest in adopting its technology. HeartBeam will also pursue a heart attack detection indication, supported by proof-of-concept data.

HeartBeam also plans to advance its on-demand 12-lead ECG extended wear monitor project—it’s developed a working prototype of its 12-lead patch. Finally, the company seeks longitudinal data by unlocking the power of the data-rich repository generated from its 3D ECG platform. It believes the ability to record synthesized 12-lead ECGs over time will create the opportunity to build artificial intelligence (AI)-based screening and prediction algorithms.

“The company wishes to thank the FDA for its expeditious and constructive engagement throughout the review and appeal process, as well as its thorough evaluation of HeartBeam’s clinical data,” said HeartBeam CEO Robert Eno. “This FDA clearance is a defining moment for HeartBeam, and the true beginning of our mission to revolutionize cardiac care. We look forward to initiating our U.S. market introduction while advancing our efforts on heart attack detection, an on-demand 12-lead extended wear patch, and AI-based screening and prediction algorithms trained on our unique longitudinal data.”

In September, the company shared new study data demonstrating the efficacy of its deep learning algorithms.